Go Back
Akebia Therapeutics, Inc. reports $26.2 million Q1 loss
By USInMinutes - May 08, 2023, 09:26 AM ET
Last Updated - Jul 18, 2023, 03:34 PM EDT
The company generated $40.10 million in quarterly revenue
Akebia Therapeutics, Inc. [AKBA] has reported fiscal Q1 loss of $26.20 million.
On a per-share basis, the DE based company said its diluted earnings are $0.14.
The Pharmaceutical Preparations firm posted revenue of $40.10 million in this period.
Also Read:
- Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights
- Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split
- Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders
- Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News